# Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

> **NCT05713994** · — · RECRUITING · sponsor: **Ze-yang Ding, MD** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** HAIC
- **DRUG:** Bevacizumab plus Atezolizumab
- **DRUG:** Bevacizumab Biosimilar IBI305 plus sintilimab
- **DRUG:** Lenvatinib
- **DRUG:** Sorafenib
- **DRUG:** Donafenib
- **DRUG:** Regorafenib
- **DRUG:** apatinib plus camrelizumab
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05713994
- **Lead sponsor:** Ze-yang Ding, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-19
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05713994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05713994, "Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05713994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*